AstraZeneca’s research turnaround is unique in global drug history. What is the secret sauce?
I became chairman in 2012 and decided to replenish the pipeline. So, we hired Pascal Soriot (the company’s Executive Director and Chief Executive Officer). He and his team have done a much better evaluation of the projects we have. He not only brought discipline in the process, but also sharp decision making, and unsentimental decisions on which projects have to go. If there’s an element of risk or failure, then try to fail fast. By doing that, you free up resources for projects that we are standing behind.
In 2012, we spent almost 90 per cent of our R&D internally. Now, overall, what we are doing in our R&D with small or medium-sized companies, if you add transactions by molecules selling projects ( joint molecule development projects), then the number is probably 50-50. So, a combination of much better decision-making and opening up has meant four-fold productivity of new drug discovery. That is the remarkable effect Pascal Soriot’s team has had on the group.
What has been your experience in drug research costs? How do you optimise costs? What’s your experience spending dollars internally and working with other partners, including Sun Pharma in India?
The cost of making a drug is always increasing. The way to offset that is to try to fail fast. The trick is to get the mix right. We are using digital tools – in India it is called AI – which is very good to screen molecules. Small chemical molecules have 25-50 atoms per molecule. In biological molecules, we are talking about 250,000 atoms per molecule. To screen these complex structures, you need a lot of computing power and digitalisation.
This story is from the January 12, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the January 12, 2020 edition of Business Today.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Haute Couture in the Kitchen
FASHION BRANDS ARE ENTERING THE RESTAURANT SPACE, AS FOOD SEEMS TO HAVE BECOME THE ULTIMATE FASHION STATEMENT
It's Personal
Mixing work and personal tasks on work machines may be a done thing for many, but it makes sense to have a dedicated device for your personal needs. Here are two such devices
INTO THE BLUE
For WTiCabs Founder and CEO Ashok Vashist, scuba diving is not just an adventure sport. It is a pathway to connect with the ocean
"Challenges are opportunities"
AMIT JAIN CO-FOUNDER & CEO CARDEKHO GROUP CarDekho Group is a digital automotive solutions provider
THE WAIT FOR HIGHER PENSION
ALMOST 18 MONTHS AFTER THE SUPREME COURT RULING, SUBSCRIBERS WHO OPTED FOR A HIGHER PENSION UNDER THE EMPLOYEES' PENSION SCHEME CONTINUE TO WAIT AS THE EPFO, FACING A STAFF CRUNCH, TRIES TO FIGURE OUT THE MATH
"It's possible to have a 25% growth out of India from now on"
Rail Europe Executive Chairman & CEO Björn Bender talks about the India market, the shift to digital, and the way ahead
Evolving Strategies
Companies need to adapt to changing times for a strong workforce
PERKS PRESSURE
IT'S NOT JUST ABOUT THE MONEY ANYMORE FOR EMPLOYEES. FROM FOUR-DAY WORK WEEKS, TO SKILLING ON THE JOB AND MENTAL WELL-BEING EXERCISES, COMPANIES ARE OFFERING A HOST OF BENEFITS TO RETAIN TOP TALENT. IS THIS ENOUGH?
FOSTERING PLURALISM
Axis Bank, with its initiatives and policies, is striving to make a holistic difference to people's careers and hone their skills too
In Keeping With The Times
With a slew of initiatives for its employees, Abbott India is working hard to build a diverse and inclusive workforce